Epigenetic-modifying agents: The potential game changers in the treatment of hematologic malignancies

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2024-09-06 DOI:10.1016/j.critrevonc.2024.104498

Tahereh Hojjatipour , Mina Ajeli , Amirhosein Maali , Mehdi Azad

{"title":"Epigenetic-modifying agents: The potential game changers in the treatment of hematologic malignancies","authors":"Tahereh Hojjatipour , Mina Ajeli , Amirhosein Maali , Mehdi Azad","doi":"10.1016/j.critrevonc.2024.104498","DOIUrl":null,"url":null,"abstract":"<div><p>Hematologic malignancies are lethal diseases arising from accumulated leukemic cells with substantial genetic or epigenetic defects in their natural development. Epigenetic modifications, including DNA methylation and histone modifications, are critical in hematologic malignancy formation, propagation, and treatment response. Both mutations and aberrant recruitment of epigenetic modifiers are reported in different hematologic malignancies, which regarding the reversible nature of epigenetic regulations, make them a potential target for cancer treatment. Here, we have first outlined a comprehensive overview of current knowledge related to epigenetic regulation’s impact on the development and prognosis of hematologic malignancies. Furthermore, we have presented an updated overview regarding the current status of epigenetic-based drugs in hematologic malignancies treatment. And finally, discuss current challenges and ongoing clinical trials based on the manipulation of epigenetic modifies in hematologic malignancies.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104498"},"PeriodicalIF":5.5000,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824002415","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Hematologic malignancies are lethal diseases arising from accumulated leukemic cells with substantial genetic or epigenetic defects in their natural development. Epigenetic modifications, including DNA methylation and histone modifications, are critical in hematologic malignancy formation, propagation, and treatment response. Both mutations and aberrant recruitment of epigenetic modifiers are reported in different hematologic malignancies, which regarding the reversible nature of epigenetic regulations, make them a potential target for cancer treatment. Here, we have first outlined a comprehensive overview of current knowledge related to epigenetic regulation’s impact on the development and prognosis of hematologic malignancies. Furthermore, we have presented an updated overview regarding the current status of epigenetic-based drugs in hematologic malignancies treatment. And finally, discuss current challenges and ongoing clinical trials based on the manipulation of epigenetic modifies in hematologic malignancies.

查看原文本刊更多论文

表观遗传修饰剂：治疗血液恶性肿瘤的潜在变革者。

血液恶性肿瘤是一种致命性疾病，由在自然发育过程中存在严重遗传或表观遗传缺陷的累积白血病细胞引起。表观遗传修饰（包括 DNA 甲基化和组蛋白修饰）对血液恶性肿瘤的形成、传播和治疗反应至关重要。据报道，在不同的血液恶性肿瘤中都存在表观遗传修饰因子的突变和异常招募，而表观遗传调控的可逆性使其成为癌症治疗的潜在靶点。在此，我们首先全面概述了目前与表观遗传调控对血液恶性肿瘤的发展和预后的影响有关的知识。此外，我们还概述了基于表观遗传的药物在血液恶性肿瘤治疗中的应用现状。最后，我们还讨论了目前在血液恶性肿瘤中基于表观遗传修饰操作的挑战和正在进行的临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.